Versartis, Inc. (VSAR)

[longx]

From the clinical results Somavaratan is working, it's just that it's not as good as Pfizer's Genotropin (9.44cm vs. 10.70cm). Since Genotropin is used daily, Ascendis's TransCon is used weekly, but Versartis's Somavaratan is used only twice/month.

Perhaps Versartis technology/IPs and existing cash resources could be valuable to it's former rival/competitor, Ascendis? Given the rise of Ascendis' marketcap in the last 3 months (currently valued at $1.89B), I guess a $300M worth of stock swap for Versatis to be merged with Ascendis, would translate Versartis share price to almost $10/share, and it's highly doable for Ascendis.

https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10089620/versartis-somavaratan-still-has-a-path-forward-cantor-r